PSME1

Proteasome activator complex subunit 1 · Q06323 · PSME1 on Sugi Atlas →

0 patent compounds predicted against PSME1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PSME1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies PHASE1RECRUITING
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies PHASE1COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma PHASE1COMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults nanNOT_YET_RECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSME1 binder may also engage these)

ProteinNameSimilarity
P97371 1.000 P97371 →
P58238 1.000 P58238 →
Q5E9G3 1.000 Q5E9G3 →
PSME2 Proteasome activator complex subunit 2 1.000 landscape →
Q4U5R3 1.000 Q4U5R3 →
Q64L94 1.000 Q64L94 →
Q863Z0 1.000 Q863Z0 →
P97372 1.000 P97372 →
Q63797 0.999 Q63797 →
Q63798 0.999 Q63798 →
Q967U1 0.994 Q967U1 →
P45966 0.988 P45966 →
Q9U2Y2 0.987 Q9U2Y2 →
P47805 0.986 P47805 →
B5E0H4 0.986 B5E0H4 →
Q60V43 0.985 Q60V43 →
A1ZB91 0.985 A1ZB91 →
A8WTE8 0.985 A8WTE8 →
Q6NLQ3 0.985 Q6NLQ3 →
Q9HDW4 0.985 Q9HDW4 →
Q23H79 0.985 Q23H79 →
Q8L7U7 0.985 Q8L7U7 →
Q9N3Q8 0.985 Q9N3Q8 →
B3DL65 0.985 B3DL65 →
Q9W1F4 0.984 Q9W1F4 →
Q7SY21 0.984 Q7SY21 →
Q5XG48 0.984 Q5XG48 →
O94376 0.984 O94376 →
Q5XG71 0.984 Q5XG71 →
O14777 0.983 O14777 →